证券代码：688202 证券简称：美迪西 公告编号：2025-032 上海美迪西生物医药股份有限公司 第四届监事会第四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 上海美迪西生物医药股份有限公司（以下简称"公司"）第四届监事会第四 次会议（以下简称"本次会议"）于 2025 年 4 月 29 日以通讯方式召开。本次会 议的通知已于 2025 年 4 月 22 日以电子邮件方式送达全体监事。本次会议由监事 会主席蒋品先生召集并主持，应出席会议监事 3 人，实际出席会议监事 3 人。本 次会议的召集、召开符合《中华人民共和国公司法》等法律、行政法规以及《公 司章程》的相关规定，会议合法有效。 二、监事会会议审议情况 会议经与会监事审议并书面表决通过了如下议案： （一）审议《关于公司<2025 年第一季度报告>的议案》 经审核，公司监事会认为公司 2025 年第一季度报告的编制和审议程序符合 法律、法规、《公司章程》和公司内部管理制度的各项规定；公司 2025 年第一季 度报告的内容与格 ...

三、分红送配方案情况 本次公司不分配不转赠。 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 6684.9万股，累计占流通股比： 49.64%，较上期变化：0.00 。 | 名称 | 持有数量(万股) | 占总股本比 | 增减情况 | | --- | --- | --- | --- | | | | 例(%) | (万股) | | 陈金章 | 1636.28 | 12.15 | 不变 | | 陈建煌 | 1203.94 | 8.94 | 不变 | | 陈春来 | 795.71 | 5.91 | 不变 | | 王国林 | 639.16 | 4.75 | 不变 | | 林长青 | 547.37 | 4.06 | 不变 | | 陈国兴 | 487.52 | 3.62 | 不变 | | CHEN CHUN-LIN | 404.22 | 3.00 | 不变 | | MEDICILON INCORPORATED | 354.08 | 2.63 | 不变 | | 施亦珺 | 347.27 | 2.58 | 不变 | | 泽丰瑞熙私募证券基金管理(广东)有限公司-泽丰广鑫1号 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 267,091,301.60, representing a year-on-year increase of 2.92% compared to CNY 259,506,479.47 in the same period last year[4]. - The net profit attributable to shareholders of the listed company improved significantly, with a loss of CNY 14,546,830.68, a reduction in loss of CNY 23,008,900.74 compared to a loss of CNY 37,555,731.42 in the previous year[4][8]. - The net cash flow from operating activities was CNY 937,658.54, a substantial improvement from a negative cash flow of CNY 58,554,399.06 in the same period last year[4][8]. - The company achieved a comprehensive gross profit margin increase due to a 12.46% reduction in operating costs, contributing to the improved financial performance[8]. - The basic and diluted earnings per share were both -CNY 0.11, an improvement from -CNY 0.28 in the same period last year[4]. - The company reported a total comprehensive loss of CNY 14,571,328.68 for Q1 2025, compared to a loss of CNY 37,430,250.14 in Q1 2024[19]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,838,255,605.65, reflecting a slight increase of 0.53% from CNY 2,823,259,680.59 at the end of the previous year[5]. - Total liabilities increased to CNY 712,669,711.29 from CNY 683,102,457.55, reflecting a rise of 4.0%[15]. - The company's total equity decreased to CNY 2,125,585,894.36 from CNY 2,140,157,223.04, a decline of 0.7%[15]. Cash Flow - Cash flow from operating activities in Q1 2025 was CNY 235,153,156.60, compared to CNY 230,385,095.15 in Q1 2024, indicating a slight increase[20]. - The net cash flow from operating activities was 937,658.54, a significant improvement compared to a net outflow of -58,554,399.06 in the previous period[21]. - Cash inflow from investment activities totaled 158,682,963.50, down from 256,129,890.04 in the prior period[21]. - The net cash flow from financing activities was 42,617,203.44, recovering from a net outflow of -45,291,688.38 previously[22]. - The total cash and cash equivalents at the end of the period were 227,345,683.05, a decrease from 310,534,580.34 at the beginning of the period[22]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 12,407[10]. - The largest shareholder, Chen Jinzhan, holds 16,362,811 shares, representing 12.15% of total shares[10]. - There are no significant changes in the top 10 shareholders or their shareholding status due to securities lending activities[11]. Research and Development - The company's R&D investment totaled CNY 24,095,479.17, accounting for 9.02% of operating revenue, a decrease from 9.57% in the previous year[5]. - Research and development expenses for Q1 2025 were CNY 24,095,479.17, slightly down from CNY 24,845,984.25 in Q1 2024[18]. - The company has not reported any new product or technology developments in this period[12]. Inventory and Receivables - Accounts receivable increased from ¥548,138,774.34 to ¥569,331,118.55, an increase of about 3.9%[13]. - Inventory decreased from ¥104,361,324.22 to ¥82,726,864.24, a reduction of approximately 20.7%[13]. - Total current assets increased slightly from ¥1,435,698,565.84 to ¥1,444,213,864.32, an increase of about 0.6%[13].

美迪西公告，股东陈建煌因自身资金需求，计划通过集中竞价或大宗交易方式减持不超过300.99万股， 占公司总股本的2.23%，减持期间为2025年5月26日至2025年8月25日。陈建煌目前持股1203.94万股，占 公司总股本的8.94%。减持价格将按市场价格确定，若期间公司发生派息、送股等事项，减持数量将相 应调整。 ...

证券代码：688202 证券简称：美迪西 公告编号：2025-031 上海美迪西生物医药股份有限公司 关于参加 2024 年度科创板创新药行业集体业绩说明 会暨召开 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 4 月 28 日（星期一）至 5 月 7 日（星期三）16:00 前登录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 IR@medicilon.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 上海美迪西生物医药股份有限公司（以下简称"公司"）已于 2025 年 4 月 22 日发布公司 2024 年度报告，将于 2025 年 4 月 30 日发布公司 2025 年第一季 度报告。为便于广大投资者更全面深入地了解公司 2024 年度和 2025 年第一季度 的经营成果、财务状况，公司计划于 2025 年 5 月 8 日（星期四）15:00-1 ...

Group 1 - The core viewpoint of the news is that the implementation plan for the digital transformation of the pharmaceutical industry in China aims to achieve comprehensive digitalization by 2030, enhancing innovation capabilities and establishing a complete industrial ecosystem [1][2] - The plan includes four major actions: empowering digital technology, promoting digital transformation, building a digital service system, and enhancing digital regulation, with 14 key tasks to improve the overall capability of the pharmaceutical industry's digital transformation [1][2] - The focus areas of the plan include pharmaceutical research and development, production, management decision-making, quality assurance, circulation and traceability, and contract research and production services, providing a clear pathway for collaboration between pharmaceutical companies and IT service providers [1][2] Group 2 - The release of the plan signifies a new phase of high-quality development driven by data and intelligent empowerment in the pharmaceutical industry, which is expected to reshape the industry landscape through technologies like AI in drug development and smart manufacturing [2] - The AI pharmaceutical market is projected to grow significantly, from $1.38 billion in 2023 to $2.994 billion by 2026, with a compound annual growth rate of 30.47% from 2021 to 2026 [3] - Major pharmaceutical companies are expected to enhance drug discovery efficiency by over 50% through AI integration, which will lead to better resource allocation in research and healthcare [3] Group 3 - Notable companies in the sector include WuXi AppTec, which is projected to achieve a revenue of 39.241 billion yuan in 2024, with a 5.2% year-on-year growth excluding COVID-19 projects [4] - Kanglong Chemical is expected to report a revenue of 12.276 billion yuan in 2024, reflecting a 6.39% year-on-year increase, while its net profit is anticipated to grow by 12.01% [4] - Yidu Technology focuses on AI in healthcare, providing innovative solutions across various fields, including public health and new drug development [4]

证券代码：688202 证券简称：美迪西 公告编号：2025-030 上海美迪西生物医药股份有限公司 关于以集中竞价交易方式首次回购公司股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 价格不超过人民币 54 元/股（含），回购股份期限为公司股东大会审议通过本次回 购股份方案之日起 6 个月内。 具体内容详见公司分别于 2024 年 12 月 28 日、2025 年 1 月 25 日在上海证券 交易所网站（www.sse.com.cn）披露的《上海美迪西生物医药股份有限公司关于以 集中竞价方式回购股份方案的公告》（公告编号：2024-062）、《上海美迪西生物医 药股份有限公司关于以集中竞价方式回购股份的回购报告书》（公告编号： 2025-011）。 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，现将公司首次回购公司股份情况公告如下： 2025 年 4 月 22 日，公司通过集中竞价交易方式首次回购股份 158,194 股，已 回购股份 ...

4月21日晚，美迪西（688202.SH）发布2024年年度报告。财务数据显示，公司2024年度实现营业总收 入10.38亿元；归属于母公司股东的净利润-3.31亿元。 美迪西表示，报告期间因医药行业投融资放缓、市场需求变化及竞争加剧，导致收入未达预期。尽管公 司严格控制成本，但盈利仍因收入降幅和成本调整不同步而下滑。此外，受宏观经济和市场环境影响， 公司计提了较大金额的减值损失，进一步影响了净利润。 在差异化发展初期，美迪西就已与其他国内领先CRO企业不同，以国内市场为抓手。2024年，公司境 内客户收入为6.44亿元，占主营业务收入62.04%，并与滨会生物、健新原力、合拓创展、上海高博肿瘤 医院、始达医药等多家大型制药企业及医院达成战略合作，共绘生物新药开发新蓝图。 此外，2024年7月，美迪西与"创新药一哥"恒瑞医药（600276）达成新分子药物（ADC/小核酸/CGT） 临床前评价战略合作。此后几个月，二者合作成果捷报频传，美迪西先后助力恒瑞医药siRNA药物 HRS-9563注射液、HRS-5817获批临床，在高血压治疗、健康减肥赛道带来新的曙光。 不仅如此，随着公司不断发展壮大，美迪西的目光逐渐 ...

Core Viewpoint - The investment by Medisi is aimed at strengthening the supply of key experimental animals through acquiring a 23% stake in Plai Biological, which specializes in breeding and selling experimental animals like macaques and crab-eating monkeys [1][2]. Group 1: Investment Details - Medisi plans to acquire a 23% stake in Plai Biological for a total amount of 21.906 million yuan [1]. - The registered capital corresponding to this stake is 23 million yuan, with a paid-in capital of 7.728 million yuan [2]. - The remaining unpaid capital of 15.272 million yuan will be settled by Medisi at a nominal fee of 1 yuan per registered capital [2]. Group 2: Company Background - Plai Biological was established in November 2022 with a registered capital of 100 million yuan and paid-in capital of 33.6 million yuan [1]. - The company is fully owned by Puxin Biological, which holds a national license for breeding key protected terrestrial wildlife [1]. Group 3: Industry Context - Medisi primarily engages in pharmaceutical research outsourcing, with experimental animals being a crucial raw material [3]. - The demand for experimental animals has surged due to the growth in the healthcare industry, leading to significant price increases for monkeys used in experiments [3]. - The price of crab-eating monkeys rose from approximately 13,500 yuan in 2018 to over 200,000 yuan in 2022, impacting Medisi's operational costs [3]. Group 4: Market Trends - In 2023, the demand for experimental monkeys has decreased, resulting in a drop in prices to 125,000 yuan, with projections for 2024 to fall below 100,000 yuan [4]. - Companies that previously stockpiled monkeys, like Zhaoyan New Drug, have faced financial challenges due to the declining value of biological assets [4].

上海美迪西生物医药股份有限公司 2024 年度独立董事述职报告 （赖卫东） 作为上海美迪西生物医药股份有限公司（以下简称"公司"）的独立董事， 2024 年度，本人严格按照《中华人民共和国公司法》（以下简称"《公司法》"）、 《上市公司独立董事管理办法》《上海证券交易所科创板股票上市规则》等法律 法规、规范性文件要求，以及《公司章程》和《独立董事工作制度》等制度规定， 忠实勤勉地履行职责，积极出席相关会议，认真审议董事会各项议案，对公司重 大事项发表了独立意见，努力维护公司股东，特别是中小股东的合法权益，充分 发挥独立董事在公司规范运作等方面的监督作用。现将 2024 年度履职总体情况 报告如下： 一、独立董事的基本情况 (一)个人工作履历、专业背景以及兼职情况 赖卫东，1958 年 1 月出生，中国国籍，无永久境外居留权，研究生学历。历 任江西师范大学教师，江西省人民政府外事办公室干部，中欧国际工商学院副主 任。现任上海科泰电源股份有限公司独立董事，中欧国际工商学院高管教育部高 级顾问。2021 年 11 月至今担任公司独立董事。 (二)独立性情况 作为公司的独立董事，本人未在公司担任除独立董事以外的任何职 ...